We pre-selected patients with advanced HER-2/neu ( HER2 ) overexpressing breast and ovarian cancers for enrolment into a phase I trial designed to evaluate the immunogenicity of a HER2 peptide vaccine based on the patient 's immune competence as assessed by DTH skin testing to common recall antigens ( Multitest CMI , Institut Merieux , Lyon , France ) .